Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.69+0.06 (+0.90%)
Close on Nov 17, 2026Market cap $441.88MP/E –Yield –
Evolus cash
Cash and short-term investments held at the end of each period.
Evolus's cash was $45.17M at Jun 30, 2026. For fiscal 2025 it was $53.83M, down 38.1% from the year before. The highest annual figure on record is $146.26M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.83M | -38.1% |
| FY2024 | Dec 31, 2024 | $86.95M | +38.4% |
| FY2023 | Dec 31, 2023 | $62.84M | +16.5% |
| FY2022 | Dec 31, 2022 | $53.92M | -63.1% |
| FY2021 | Dec 31, 2021 | $146.26M | +36.0% |
| FY2020 | Dec 31, 2020 | $107.56M | -17.1% |
| FY2019 | Dec 31, 2019 | $129.80M | +39.3% |
| FY2018 | Dec 31, 2018 | $93.16M | – |
| FY2017 | Dec 31, 2017 | $0 | -100.0% |
| FY2016 | Dec 31, 2016 | $187.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $45.17M | -26.8% |
| Q1 FY2026 | Mar 31, 2026 | $49.79M | -26.7% |
| Q4 FY2025 | Dec 31, 2025 | $53.83M | -38.1% |
| Q3 FY2025 | Sep 30, 2025 | $43.52M | -48.8% |
| Q2 FY2025 | Jun 30, 2025 | $61.74M | -34.1% |
| Q1 FY2025 | Mar 31, 2025 | $67.89M | -30.0% |
| Q4 FY2024 | Dec 31, 2024 | $86.95M | +38.4% |
| Q3 FY2024 | Sep 30, 2024 | $85.04M | +119.8% |
| Q2 FY2024 | Jun 30, 2024 | $93.67M | +124.6% |
| Q1 FY2024 | Mar 31, 2024 | $96.96M | +208.2% |
| Q4 FY2023 | Dec 31, 2023 | $62.84M | +16.5% |
| Q3 FY2023 | Sep 30, 2023 | $38.69M | -41.0% |
| Q2 FY2023 | Jun 30, 2023 | $41.71M | -50.6% |
| Q1 FY2023 | Mar 31, 2023 | $31.46M | -70.5% |
| Q4 FY2022 | Dec 31, 2022 | $53.92M | -63.1% |
| Q3 FY2022 | Sep 30, 2022 | $65.57M | -39.2% |
| Q2 FY2022 | Jun 30, 2022 | $84.48M | -35.9% |
| Q1 FY2022 | Mar 31, 2022 | $106.67M | +381.1% |
| Q4 FY2021 | Dec 31, 2021 | $146.26M | +36.0% |
| Q3 FY2021 | Sep 30, 2021 | $107.80M | -2.1% |
| Q2 FY2021 | Jun 30, 2021 | $131.74M | +55.4% |
| Q1 FY2021 | Mar 31, 2021 | $22.17M | -77.7% |
| Q4 FY2020 | Dec 31, 2020 | $107.56M | -17.1% |
| Q3 FY2020 | Sep 30, 2020 | $110.12M | +48.8% |
| Q2 FY2020 | Jun 30, 2020 | $84.75M | -15.2% |
| Q1 FY2020 | Mar 31, 2020 | $99.64M | +83.3% |
| Q4 FY2019 | Dec 31, 2019 | $129.80M | +39.3% |
| Q3 FY2019 | Sep 30, 2019 | $74.03M | -29.6% |
| Q2 FY2019 | Jun 30, 2019 | $99.90M | +129.2% |
| Q1 FY2019 | Mar 31, 2019 | $54.37M | +9.7% |
| Q4 FY2018 | Dec 31, 2018 | $93.16M | – |
| Q3 FY2018 | Sep 30, 2018 | $105.17M | – |
| Q2 FY2018 | Jun 30, 2018 | $43.59M | – |
| Q1 FY2018 | Mar 31, 2018 | $49.57M | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | -100.0% |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $187.00K | – |
See a number that looks wrong?